NEW YORK (GenomeWeb) – Biocept said today that it has partnered with the Addario Lung Cancer Medical Institute (ALCMI) to evaluate the use of the company’s Target Selector liquid biopsy platform in a clinical study of lung cancer patients.
The Target Selector technology is designed to analyze both circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) biomarkers from a blood sample. Under the terms of the deal, ALCMI and collaborating institutions will send samples from up to 400 lung cancer patients to Biocept, which will use the platform to detect and assess key biomarkers with the goal of demonstrating the concordance of liquid biopsy to solid tissue biopsies at de novo presentation.
This concordance will validate the use of a liquid biopsy sample when biopsy tissue is depleted or difficult to obtain for biomarker stratification, Biocept said. The trial also aims to validate the utility of monitoring key biomarkers in lung cancer patients with a liquid biopsy, enumerating CTC counts, and quantifying ctDNA mutations in order to illustrate drug response, predict treatment failure prior to progression observed with radiographic imaging, and identify resistance mutations.
The company said that the trial will distinguish between advanced non-small cell lung cancer (NSCLC)